Answers are grounded in this paper and cite their sources.
Antiviral, Immunomodulator, or Both?See Article on Page 1160 R ibavirin (1-b-d-ribofuranosyl-1,2,4-triazole-3carboxamide; RBV) is a guanosine analog with broad-spectrum virustatic activity originally developed for the treatment of severe respiratory syncytial virus infection.1 The drug has since been empirically used, with varying degrees of proven clinical efficacy, for the treatment of several RNA virus infections, including Lassa fever and other arenaviruses, Crimean-Congo hemorrhagic fever, La Crosse encephalitis, influenza, adenovirus, and hepatitis E virus (reviewed in earlier studies 2,3 ).However, beneficial effects in these clinical settings are often controversial, and clinical trials are, for obvious reasons, largely missing.Various mechanisms of action of RBV have been suggested, including direct inhibition of viral RNAdependent RNA polymerases, inhibition of host inosine monophosphate dehydrogenase, inhibition of viral capping enzymes, and, last but not least, induction of lethal mutagenesis (i.e., the point at which the number of mutations per genome is too large to allow viability of newly assembled virions).4 However, the overwhelming success of RBV largely derives from its excellent performance in synergy with standard or pegylated interferon-alpha (Peg-IFN-a)-based therapies leading to dramatic improvement in sustained virological response (SVR) rates among patients with chronic hepatitis C virus (HCV) infection, 2,5 which has been extended to combination treatment with first-6,7 and second-generation 8 direct-acting antivirals, and, very
No takes yet. Share an insight, caveat, or question.
Mario Umberto Mondelli (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: